Inflammatory Bowel Disease (IBD) is a chronic condition that includes Crohn’s disease and ulcerative colitis. Symptoms are often invisible and unpredictable, making it difficult for clinicians and patients to understand what’s happening inside the bowel. Imaging plays a central role in diagnosis and monitoring, but traditional methods can be subjective, time-consuming, and invasive.

Motilent develops imaging tools that bring greater clarity and objectivity to IBD assessment - supporting better decisions for clinicians, patients, and researchers.

Clinical and research challenges

IBD assessment is complex for both clinicians and researchers.

Symptoms don't tell the full story

Patients may feel unwell despite limited visible inflammation, or conversely, feel fine while inflammation persists. This mismatch makes symptoms alone an unreliable measure.

Endoscopy is invasive and limited

While colonoscopy and biopsy remain gold standards, they are uncomfortable, costly, and only examine limited bowel regions. They are also prone to inter-observer variation.

Imaging generates large, complex datasets

MRI and intestinal ultrasound are increasingly used for whole-bowel assessment, but cine loops and dynamic scans can be time-consuming to review and difficult to standardise.

Other modalities are under-utilised

Capsule endoscopy and histopathology provide valuable information, but data are hard to integrate with imaging and clinical findings.

Clinical trials need reproducible endpoints

Variability in how images and biopsies are interpreted makes it difficult to run efficient multi-centre trials. Consistent biomarkers are needed to support regulatory acceptance.

Patient perspectives are often missed

Patient-reported outcomes (PROs) are critical for understanding real-life disease burden, but collection and integration remain inconsistent.

Together, these approaches make IBD assessment more transparent, reproducible, and meaningful - for clinicians, researchers, and patients.

Explore our products

Motilent is transforming how IBD is measured, monitored, and understood - across clinical care, research, and patient engagement.

Publications and evidence

Validated in Crohn’s disease

Multiple peer-reviewed studies show that small bowel motility measured with GIQuant correlates with inflammation and treatment response in Crohn’s disease.

Used in international clinical trials

GIQuant has been adopted as an imaging endpoint in multi-centre Crohn’s disease trials, supporting objective and reproducible outcome measures for regulatory submission.

Expanding research pipeline

Motilent is exploring integration of MRI, intestinal ultrasound, capsule endoscopy, and histopathology, as well as patient-reported outcomes via IBDmate, to create a more comprehensive understanding of IBD activity.